Combined Whey Protein and Collagen Supplementation in Resistance-Trained Men
NCT ID: NCT07171411
Last Updated: 2025-09-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
40 participants
INTERVENTIONAL
2024-01-03
2024-04-10
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The primary outcome was muscle mass, measured with bioelectrical impedance analysis (BIA). Secondary outcomes included bone mineral density (DXA scans), maximal strength (1RM squat and bench press), and blood markers of bone turnover (P1NP and CTX-I).
Results showed that the whey + collagen group achieved the largest improvements in muscle growth, lumbar spine bone mineral density, strength, and favorable changes in bone turnover markers compared to all other groups. No serious side effects were reported, and supplement adherence was very high.
These findings suggest that combining whey protein and collagen may be a practical strategy to support muscle and bone adaptation in resistance-trained men.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effect of Collagen Peptides, in Combination With Resistance Training, on Body Composition and Muscle Strength in Untrained Men
NCT06061315
Effects of a Multi-ingredient Supplement Study: a Randomized Controlled Trial in Men and Women
NCT03525197
Effects of Whey and Collagen Protein Blend on Protein Synthesis Rates
NCT05386771
Effects of Whey Protein and Collagen Supplementation
NCT04213586
The Effects of Whey vs. Collagen on MPS
NCT03281434
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Forty healthy male participants (18-35 years, with ≥1 year of resistance training experience) were recruited and randomized into four parallel groups (n=10 per group):
Whey Protein + Collagen (30 g WP + 10 g collagen/day)
Whey Protein only (30 g/day)
Collagen only (10 g/day)
Placebo (10 g maltodextrin/day, isocaloric)
All supplements were provided in identical single-dose sachets to ensure blinding. Participants consumed one dose upon waking and one post-exercise (or same time on rest days). A standardized, supervised hypertrophy-oriented resistance training program (3 sessions/week for 8 weeks) was applied to all groups.
Primary outcome: Muscle mass (lean body mass, assessed with BIA at baseline and 8 weeks).
Secondary outcomes: Lumbar spine and femoral neck BMD (DXA), maximal squat and bench press strength (1RM), and serum biomarkers of bone turnover (P1NP and CTX-I).
The trial was approved by the Islamic Azad University IRB (Protocol No: IAU.Ilk.C.162911421.2024). All participants gave written informed consent. Compliance with supplementation was \>90% and training adherence was \>95%. No adverse events were reported.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Whey Protein + Collagen (WP+C)
Participants received 30 g/day whey protein isolate plus 10 g/day type I \& III collagen peptides, split into two daily doses (morning and post-exercise or at same time on rest days). Supplements were packaged in identical sachets.
Whey Protein + Collagen
Participants consumed 30 g/day whey protein isolate (Optimum Nutrition) combined with 10 g/day type I \& III collagen peptides (Vital Proteins). Supplements were provided as single-dose sachets, identical in appearance, and taken twice daily (morning and post-exercise or same time on rest days) for 8 weeks.
Whey Protein Only (WP)
Participants received 30 g/day whey protein isolate, split into two daily doses. Packaged identically to other interventions to maintain blinding.
Whey Protein
Participants consumed 30 g/day whey protein isolate (Optimum Nutrition), in identical sachets, taken twice daily for 8 weeks.
Collagen Only (C)
Participants received 10 g/day type I \& III collagen peptides, split into two daily doses. Identical packaging ensured blinding.
Collagen Peptides
Participants consumed 10 g/day type I \& III collagen peptides (Vital Proteins), in identical sachets, taken twice daily for 8 weeks.
Placebo (P)
Participants received 10 g/day maltodextrin (isocaloric with protein groups), provided in identical sachets to ensure blinding.
Maltodextrin (Placebo)
Participants consumed 10 g/day maltodextrin powder (isocaloric to protein supplements), packaged identically, taken twice daily for 8 weeks.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Whey Protein + Collagen
Participants consumed 30 g/day whey protein isolate (Optimum Nutrition) combined with 10 g/day type I \& III collagen peptides (Vital Proteins). Supplements were provided as single-dose sachets, identical in appearance, and taken twice daily (morning and post-exercise or same time on rest days) for 8 weeks.
Whey Protein
Participants consumed 30 g/day whey protein isolate (Optimum Nutrition), in identical sachets, taken twice daily for 8 weeks.
Collagen Peptides
Participants consumed 10 g/day type I \& III collagen peptides (Vital Proteins), in identical sachets, taken twice daily for 8 weeks.
Maltodextrin (Placebo)
Participants consumed 10 g/day maltodextrin powder (isocaloric to protein supplements), packaged identically, taken twice daily for 8 weeks.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* At least 1 year of consistent resistance training experience (≥3 sessions per week, targeting major muscle groups)
* Healthy, with no history of musculoskeletal, metabolic, or cardiovascular disorders
* No current or recent (\<6 months) use of anabolic steroids, growth hormones, or performance-enhancing substances
* Non-smoker and no habitual use of anti-inflammatory medications
* Able and willing to comply with supplementation and supervised training program
* Provided written informed consent
Exclusion Criteria
* Recent fractures or surgeries affecting musculoskeletal health (\<6 months)
* Known allergy or intolerance to dairy proteins or collagen supplements
* Inability to attend scheduled supervised resistance training sessions
* Non-adherence to dietary control requirements (e.g., use of additional protein/creatine supplements during study)
* Any condition deemed by investigators to interfere with study compliance or safety
18 Years
35 Years
MALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Saglik Bilimleri Universitesi
OTHER
Islamic Azad University of Mashhad
OTHER
Manisa Celal Bayar University
OTHER
Muş Alparslan University
OTHER
Pamukkale University
OTHER
Australian Catholic University
OTHER
Ankara Yildirim Beyazıt University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Health Sciences
Ankara, Etlik, Turkey (Türkiye)
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IAU.Ilk.C.162911421.2024
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.